New preventive medical treatment for childhood myopia

Klaus Trier, MD, ophthalmologist
Tingskiftevej 6
DK-2900 Hellerup
Denmark

Mail: ktrier@dadlnet.dk

The length of the human eye increases from 17 mm at birth to normally 24 mm at the age of 14 years. Among myopic children, however, the rate of growth is too high, and the growth continues until 18-20 years of age, at which time the length of the myopic eye may exceed 30 mm. At 18-20 years of age general maturation of the connective tissue of the body (cross-linking of collagen) normally prevents further elongation of the eye, and the myopia becomes stable.


Beside being a troublesome handicap demanding optical correction, myopia causes an increased risk of complications later in life. Because of these complications (retinal detachment, macular degeneration, glaucoma) myopia is one of the leading causes of blindness. Out of the 600 cases of retinal detachment ocurring in Danmark every year (population 5 mio.), it is estimated that 300 would be eliminated if myopia exceeding -3 diopter could be prevented. In addition, a great number of cases of macular degeneration and glaucoma could be avoided. Correction of myopia with eyeglasses, contact lenses, laser treatment or implantation of intraocular lenses does not prevent these complications. The use of contact lenses or laser treatment of the cornea may in rare cases deteriorate vision because of damage to the cornea.


In later years, experimental results have shed light on the mechanism by which the growth of the eye is controlled. In order to obtain a focused image on the retina, the length of the eye has to correspond with the refraction of light by the cornea and the lens within a tolerance of 0.1 mm. Because this degree of precision cannot be obtained by genetic programming, a feed-back mechanism is operating to ensure continued optimal function of the eye. Thus, the rate of growth of the eye is regulated in response to the amount of defocusing registred by the retina. If the eye is hypermetropic, the collagen in the sclera will be degraded, thereby softening the wall of the eye. Because the softened sclera will yield to the intraocular pressure, the eye becomes longer. When the appropiate length of the eye has been reached, collagen production in the sclera is stimulated, and eye growth stops.


In myopic children, this mechanism is out of balance, and the content of collagen in the sclera is therefore permanently reduced. Because of this, the length of the eye will increase with up to 1 mm per year compared with the normal growth rate of 0.1 mm per year. The average growth rate of the eye among Danish myopic children in the age 8-14 years is around 0.3 mm per year, and the corresponding progression of myopia around 0.5 diopters per year.


A treatment that increases the content of collagen in the sclera will therefore work against the progression of myopia. A metabolite of caffeine, 7-methylxanthine, which is naturally present in the cocoa fruit, not only increases the content of collagen in the sclera of rabbits, but also prevents the development of myopia in guinea pigs. In contrast to caffeine, 7-methylxanthine does not reach the brain, and therefore has no stimulatory effect on the behavior.


A 36-months clinical trial completed by 61 myopic children (average 11 years) have shown that treatment with 7-methylxanthine reduces the growth-rate of the eye by around 50% over two years. As long as the treatment is continued, the growth-rate of the eye and the progression rate of the myopia drops, but when the treatment is stopped, this effect disappears.

In the second year of treatment, among 10-13 year old myopic children, 47% of those treated with 7-methylxanthine had stable myopia (<0.25 diopters per year) compared to 17% of those treated with placebo. Correspondingly, in the second year of treatment, 44% of those treated with 7-methylxanthine had a normal growth rate of the eye (<0.15 mm per year) compared to 14% of those treated with placebo. These results were obtained with a dose of one tablet of 400 mg once per day. Preliminary results suggest that the effect of one tablet twice per day is considerably better.

No side-effects of the treatment were found.


The treatment is available in Denmark as a prescription drug. In order to evaluate the effect of the treatment, it is useful to measure the eye growth and the myopia progression before treatment is started or during the first 6 months of treatment, and then once per year. The dose is 400 mg every morning and evening. The treatment should be continued until 18 years of age. In case of pregnancy, however, the treatment should be discontinued. In case of severe chronic conditions, like diabetes or epilepsy, the treatment should also be discontinued.


It is important to start the treatment as early as possible, since the myopia that has already developed cannot be reduced. Unfortunately, the myopia is often not found before it has reached a level of around -1 diopter. Normally, a child at 7 years of age will have a slight degree of hypermetropia, around +1 diopter. If, however, there is no hypermetropia at this age, it is almost certain that the child will eventually develop myopia. Children should therefore, especially if one or both of the parents are myopic, be examined at the age of 7 years, and if no hypermetropia is found they should be closely followed.

 

Links to scientific literature:

 

Trier K, Olsen EB, Kobayashi T, Ribel-Madsen SM. Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide, or l-ornithine. Br J Ophthalmol 1999;83:1370-1375

https://www.ncbi.nlm.nih.gov/pubmed/10574816

 

Trier K, Ribel-Madsen SM, Cui D, Christensen SB. Systemic 7-methylxanthine in retarding axial eye growth and myopia progression: a 36-months pilot study. J Ocul Biol Dis Inform 2008;1:85-93
http://www.springerlink.com:80/content/h476385114352313/

 

Cui D, Trier K, Zeng J, Wu K, Yu M, Hu J, Chen X, Ge J. Effects of 7-methylxanthine on the sclera in form deprivation myopia in guinea pigs. Acta Ophthalmol 2011;89:328-34

http://www.ncbi.nlm.nih.gov/pubmed/19860777

 

Nie H, Huo L, Yang X, Zeng J, Trier K, Cui D. Effects of 7-methylxanthine on form-deprivation myopia in pigmented rabbits. Int J Ophthalmol 2012;5:133-37

https://www.ncbi.nlm.nih.gov/pubmed/22762036

 

Cui D, Trier K, Ribel-Madsen SM. Effect of day length on eye growth, myopia progression, and change of corneal power in myopic children. Ophthalmology 2013;120:1074-9

http://www.ncbi.nlm.nih.gov/pubmed/23380471

 

WHO Technical report 2015

http://www.who.int/blindness/causes/MyopiaReportforWeb.pdf?ua=1

 

Hung L-F, Arumugam B, Ostrin L, Patel N, Trier K, Jong M, Smith EL III. The adenosine receptor antagonist, 7-methylxanthine, alters emmetropizing responses in infant macaques. Invest Ophthalmol Vis Sci. 2018;59:472-486

http://iovs.arvojournals.org/article.aspx?articleid=2670518

 

Wildsoet CF, Chia A, Cho P, Guggenheim JA, Polling JR, Read S, Sankaridurg P, Saw SM, Trier K, Walline JJ, Wu PC, Wolffsohn JS. IMI - Interventions for controlling myopia onset and progression report. Invest Ophthalmol Vis Sci 2019;60:M132-M160

https://iovs.arvojournals.org/article.aspx?articleid=2727315

Logo/